6275 Nancy Ridge Drive, Suite 110
About Organovo, Inc.
Organovo (NASDAQ MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications.
The Company is collaborating with a variety of pharmaceutical, academic and other partners to develop human biological tissues in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed safer, faster and at lower cost. In addition to numerous scientific publications, our technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and other outlets.
Organovo is changing the shape of life sciences, medical research and practice. Check out our current openings to see how you can “Change the Shape of Your Future at Organovo”.
115 articles with Organovo, Inc.
Organovo Holdings, Inc. (“Organovo” or the “Company”) (Nasdaq: ONVO) announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market (the “ Minimum Bid Price Requirement ”). On September 2, 2020, Organovo received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, Inc. stating that because Organovo’s common stock had a closing bid price at or a
Organovo Holdings, Inc. (the “Company”) (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The shares underlying the Company’s outstanding options and restricted stock unit awards will also be adjusted accordingly. The reverse stock split will take effect at 5:00 pm (Easter
Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda Therapeutics
Believes Stockholders Sent a Loud and Clear Message at Special Meeting That They Oppose This Value-Destructive Combination
Organovo Holdings, Inc. convened, on March 26, 2020, the special meeting of stockholders and then adjourned the Special Meeting until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposals Nos. 1 and 4.
Organovo Holdings, Inc. convened, on March 26, 2020, the special meeting of stockholders and then adjourned the special meeting of stockholders until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposal Nos. 1 and 4.
Organovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to Stockholders
Believes the Board, Which Has Presided Over Significant Value Destruction in Recent Years, Has Asked Stockholders to Take an Unnecessary Risk Without Offering a Compelling Rationale
Feb. 26, 2020 13:30 UTC Recommends Stockholders Vote "FOR" Proposed Merger with Tarveda SAN DIEGO--( BUSINESS WIRE )-- Organovo Holdings, Inc. (“Organovo”) (NASDAQ: ONVO) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission and has mailed these materials and a letter to its stockholders in connection with the company’s Special Meeting to be held on March 26, 2020. Stockholders of record as of February 14, 2020 will be
Organovo, pointing to hurdles and timeline changes in the development of its human liver tissue for transplant, announced in August 2019 that it would seek strategic alternatives.
Keith Murphy, founder, former CEO and Chairman Emeritus of Organovo, says bioprinting and similar technologies are going strong and still growing
The collaboration will focus on expanding the use of 3D bioprinted stem cell-based therapeutic tissues. The goal is to develop treatments for end-stage renal disease.
A recent survey by the Pew Research Center found that 57 percent of Americans surveyed thought it was appropriate to use genetically engineered animals to grow organs for human transplants.
An article published earlier this summer in the Journal of Dental Research suggests that “bioengineered tooth buds” are a “superior alternative tooth replacement therapy.” In the article “Bioengineered Tooth Buds Exhibit Features of Natural Tooth Buds,” the authors report that artificial implants...
Organovo Holdings, Inc. announced the grant of inducement awards on August 14, 2018 to Dr. Steven G. Hughes, its new chief medical officer.
Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019
Organovo Holdings, Inc. announced that Steven G. Hughes has been named Chief Medical Officer. Dr. Hughes is an industry veteran who brings significant experience directing clinical development and medical affairs teams at leading biopharma companies.
There has been recent coverage of 3D bioprinting and how it has the potential to create a brave new world of printed organs to be used in biopharma research and maybe someday to even be used in organ transplants.
Organovo today reported financial results for the fiscal third quarter of 2018 and updated its full-year fiscal 2018 outlook.
In advance of the call on February 8, 2018, Organovo will issue its fiscal third-quarter 2018 earnings press release, which will be available at http://www.organovo.com.
Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency
Organovo is now qualified to receive significant benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs.
Organovo Announces Fiscal Second-Quarter 2018 Results; Company Shifts Commercial Focus to Higher-Value Disease Modeling Opportunities and Updates Full-Year Fiscal 2018 Outlook
The Company is shifting the focus of its commercial and platform development efforts toward higher-demand and higher-value disease modeling services, and is deprioritizing routine toxicology research services.